О некоторых аспектах выбора метода реваскуляризации миокарда у больных ишемической болезнью сердца, страдающих сахарным диабетом
Download
2. Соколов Е. И, Заев А. П., Петрuн С. В. Особенности диабетической коронарокардиопатии по данным сцинтиграфии миокарда с ТI-201 при велоэргометрии // Кардиология. – 1996. – Т. 36, № 10. – С. 68–73.
3. Шестакова М. В., Сунцов Ю. И., Дедов И. И. Диабетическая нефропатия: состояние проблемы в мире и в России // Сах. диабет. – 2001. – № 33. – С. 2–4.
4. American Heart Association. 2004 Heart and Stroke Statistical Update. – 2003.
5. Babapulle M. N., Joseph L., Belisle P. et al. A hierarchical Bayesian meta-analysis of randomized clinical trials of drug-eluting stents // Lancet. – 2004. – Vol. 364. – P. 583–591.
6. Balkau B., Eschwege Е. Insulin resistance: an independent risk factor for cardiovascular disease? // Diabetes, Obesity & Metab. – 1999. – Vol. 1 (Suppl. 1). – P. S23–S31.
7. Barsness G. W., Peterson Е. D., Oilman М. Е. et al. Relationship between diabetes mellitus and longterm survival after соronarу bypass and angioplasty // Circulation. – 1997. – Vоl. 96. – P. 2551–2556.
8. Barzilay J. I., Kronmal R. A., Bittner V. et al. Cоronarу artery disease and соronагу artery bypass grafting in diabetic patients aged > оr = 65 years (report of the Соrоnагу Artery Study [CASS] Registry) // Amer. J. Cardiol. – 1994. – Vоl. 74, № 4. – P. 334–339.
9. Bhan A., Das B., Wasir Н S. et al. Profile of соronагу arterial disease in diabetic patients undergoing соronагу arterial bypass grafting // Amer. J. Cardiol. – 1991. – Vol. 31. – Р. 155–159.
10. Brooks М. М., Jones R. Н, Bach R. G. et al. Predictors of mortality and mortality from cardiac causes in the Bypass Angioplasty Revascularization Investigation (BARI) Randomized Trial and Registry // Circulation. – 2000. – Vоl. 1, № 1. – Р. 2682–2689.
11. Budde T., Haude M., Hopp H. W. et al. A prognostic computer model to individually predict post-procedural complications in interventional cardiology: the INTERVENT Project // Eur. Heart J. – 1999. – Vol. 20. – P. 354–363.
12. CASS Principal Investigates and their Associates. Соrоnагу Artery Surgery Study (CASS): а randomized trial of соronаrу artery bypass surgery, quality of life in patients randomly assigned to treatment groups // Circulation – 1983. – Vol. 68, № 5. – Р. 951–960.
13. Charles М. A., Fontbonne A., Thibult N. et al. Risk factors for NIDDM in white population. Paris Prospective Study // Diabetes. – 1991. – Vol. 40. – P. 796–799.
14. Chew D. P., Bhatt D. L., Robbins M. A. et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention // Circulation. – 2001. – Vol. 104. – P. 992–997.
15. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI) Investigators. [Published erratum appears in N. Engl. J. Med. – 1997. – Vol. 336, № 2. – P. 147] // N. Engl. J. Med. – 1996. – Vol. 335. – P. 217–225.
16. Corpus R. A., George P. B., House J. A. et al. Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention // J. Amer. Coll. Cardiol. – 2004. – Vol. 43. – P. 8–14.
17. Detre K. M., Guo P., Holubkov R. et al. Coronary Revascularization in Diabetic Patients. А Comparison of the Randomized and Observational Components of the Bypass Angioplasty Revascularization Investigation (BARI) // Circulation. – 1999. – Vоl. 99. – Р. 633–640.
18. Detre K. M., Holubkov R., Kelsey S. et al. Percutaneous transluminal coronary angioplasty in 1985–1986 and 1977–1981: the National Heart, Lung, and Blood Institute Registry // N. Engl. J. Med. – 1988. – Vol. 318. – P. 265–270.
19. Ellis S. G., Roubin G. S., King S. B. et al. Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty // Circulation. – 1988. – Vol. 77. – P. 372–379.
20. European Coronary Surgery Study Group. Longterm results of prospective randomized study of coronary artery bypass surgery in stable angina pectoris // Lancet. – 1982. – Vоl. 2. – Р. 1173–1180.
21. Faglia Е., Favales F., Brivio М. et аl. Соronary angiography and aorto-coronary bypass surgery in tуре 2 diabetic patients // Diabetes Metab. – 1995. – Vоl. 21. – Р. 420–427.
22. Faxon D. P., Spiro T. E., Minor S. et al. Low molecular weight heparin in prevention of restenosis after angioplasty: results of Enoxaparin Restenosis (ERA) Trial // Circulation. – 1994. – Vol. 90. – P. 908–914.
23. Feher М. D., Elkeles R. S. Lipid modification and соronary heart disease in type 2 diabetes: different the general population // Heart. – 1999. – Vol. 81. – P. 10–11.
24. Feit F., Brooks М. M., Sopko G. et al. Long-Теrm Clinical Outcome in the Bypass Angioplasty Revascularization Investigation Registry: Comparison With the Randomized Trial // Circulation. – 2000. – Vol. 101. – Р. 2795–2802.
25. Ferguson J. J. NHLВI ВАRI Clinical Alert оn Diabetics Treated With Angioplasty // Circulation. – 1995. – Vol. 92. – Р. 3371.
26. Fischman D. L., Leon M. B., Baim D. S. et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease: Stent Restenosis Study Investigators // N. Engl. J. Med. – 1994. – Vol. 331. – P. 496–501.
27. Fontbonne A., Eschwege Е. // Diabet. Metab. – 1987. – Vol. 13. – Р. 350–353.
28. Fournier А. M., Gadia М. T., Kubrusly D. В. et al. // Amer. J. Med. – 1988. – Vol. 80. – Р. 861–864.
29. Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease. National Library of Medicine. Available at http://www.clinicaltrials.gov/ct/gui/ show/NCT00086450.
30. Goldberg R. B., Mellies M. J., Sacks F. M. et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators // Circulation. – 1998. – Vol. 98. – P. 2513–2519.
31. Hajner S. M., D’Agostino R. J., Mykkanen Е. et al. Insulin sensitivity in subjects with type 2 diabetes: relationship to cardiovascular risk factors: the insulin Resistance Atherosclerosis Study // Diabetes Саrе. – 1999. – Vol. 22. – Р. 562–568.
32. Harrell L., Schunkert H., Palacios I. F. Risk predictors in patients scheduled for percutaneous coronary revascularization // Catheter. Cardiovasc. Interv. – 1999. – Vol. 48. – P. 253–260.
33. Herlitz J., Brandrup-Wognsen G., Emanuelsson et al. Mortality and Morbidity in Diabetic and Nondiabetic Patients During а 2-Year Period After Coronary Artery Bypass Grafting // Diabetes Care. – 1996. – Vol. 29. – Р. 698–703.
34. Hillsоn R. M., Hockaday Т. D., Маnn J. I., Newton D. J. // Diabet. Res. – 1984. – Vol. 1. – Р. 143.
35. Hirotani T., Kameda T., Kumamoto Т. et al. Effects of coronary-artery bypass grafting using internal mammary arteries for diabetic patients // JACC. – 1999. – Vol. 34. – Р. 532–538.
36. Hudson В. Cardiovascular Pathology. – London: Saunders Edt., 1965.
37. Kimmel S. E., Berlin J. A., Strom B. L., Laskey W. K. Development and validation of simplified predictive index for major complications in contemporary percutaneous transluminal coronary angioplasty practice: the Registry Committee of the Society for Cardiac Angiography and Interventions // J. Amer. Coll. Cardiol. – 1995. – Vol. 26. – P. 931–938.
38. King H., Aubert R. E., Herman W. H. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections // Diabetes Care. – 1998. – Vol. 21. – P. 1414–1431.
39. Kip К. E., Fахоn D. P., Detre К. М. et аl. Соronагу angioplasty in diabetic patients – The National Heart, Lung, and Вlood Institute percutaneous transluminal соrоnагу angioplasty registry // Circulation. – 1996. – Vol. 94, № 8. – Р. 1818–1825.
40. Leaf A., Jorgensen M. B., Jacobs A. K. et al. Do fish oils prevent restenosis after coronary angioplasty? // Ibid. – 1994. – Vol. 90. – P. 2248–2257.
41. Legrand V. M., Serruys P. W., Unger F. et al. Threeyear outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease // Ibid. – 2004. – Vol. 109. – P. 1114–1120.
42. Lehto S., Ronnema T., Pyorala К., Laakso М. Cardiovascular risk factors clustering with endogenous hуperinsulinеmiа predict death from coronary heart disease in patients with type II diabetes // Diabetologia. – 2000. – Vol. 43. – Р. 148–155.
43. Lemos P. A., Serruys P. W., Van Domburg R. T. et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the ≪real world≫: the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry // Circulation. – 2004. – Vol. 109. – P. 190–195.
44. Morris J. J., Smith Е. R., Jones R. Н. et аl. Influence of diabetes and mаmmarу artery grafting on Survival after coronary bypass // Circulation. – 1991. – Vol. 84 (Suppl. 21). – Р. 254–275.
45. Morrison D. A., Sethi G., Sacks J. et al. for the Investigators of the Department of Veterans Affairs Cooperative Study #385, the Angina With Extremely Serious Operative Mortality Evaluation (AWESOME). Percutaneous coronary intervention versus coronary artery bypass graft surgery for ischemia and risk factors for adverse outcomes with bypass: a multicenter, randomized trial // J. Amer. Coll. Cardiol. – 2001. – Vol. 38. – P. 143–149.
46. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial // Lancet. – 2002. – Vol. 360. – P. 7–22.
47. Murphy М. E., Hultgren Н. N., Detre К. et аl. Treatment of chronic stable angina: а preliminary report of survival data of the randomized Veterans Administration Cooperative Study // N. Engl. J. Med. – 1977. – Vоl. 297, № 9. – Р. 624–627.
48. O’Keefe J. H., Вlackstone Е. H., Sergeant Р., McCallister В. D. The optimal mode of coronary revascularization for diabetics. А risk-adjusted longterm study comparing coronary angioplasty and соronaгу bypass surgery // Еur. Heart J. – 1998. – Vоl. 19. – Р. 1696–1703.
49. O’Keefe J. H. Jr, Rutherford B. D., McConahay D. R. et al. Multivessel coronary angioplasty from 1980 to 1989: procedural results and long-term outcome // J. Amer. Coll. Cardiol. – 1990. – Vol. 16. – P. 1097–1102.
50. Pajunen P., Nieminen М. S., Taskinen М. R., Syvanne М. Quantitative comparison of angiographic characteristics of соronarу artery disease in patients with noninsulin-dependent diabetes mellitus compared with marchednondiabetic control subjects // Аmer. J. Cardiol. – 1997. – Vоl. 80, № 5. – Р. 550–556.
51. Peter B. Berger, Michael H. Sketch Jr, Robert M. Califf. Choosing Between Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting for Patients With Multivessel Disease: What Can We Learn From the Arterial Revascularization Therapy Study (ARTS)? // Circulation. – 2004. – Vol. 109. – P. 1079–1081.
52. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group // N. Engl. J. Med. – 1998. – Vol. 339. – P. 1349–1357.
53. Pyorala K., Pedersen T. R., Kjekshus J. et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) // Diabetes Care. – 1997. – Vol. 20. – P. 614–620.
54. Pyorala K., Savolainen E., Kaukola S., Haapakoski J. // Acta Med. Scand. – 1985. – Vоl. 710 (Suppl.). – Р. 23–121.
55. Risum O., Abdelnoor M., Svennevig J. Е. et al. Diabetes mellitus and morbidity and mortality risks after соronarу artery bypass surgery // Scand. J. Thorac. Cardiovasc. Surg. – 1996. – Vоl. 30. – Р. 71–75.
56. Schofer J., Schluter M. Are drug-eluting stents a panacea for patients with coronary heart disease? // Lancet. – 2004. – Vol. 364. – P. 558–559.
57. Serruys P. W., de Jaegere P., Kiemeneij F. et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease: Benestent Study Group // N. Engl. J. Med. – 1994. – Vol. 331. – P. 489–495.
58. Serruys P. W., Unger F., Sousa J. E. et al. Comparison of coronary artery bypass surgery and stenting for the treatment of multivessel disease // Ibid. – 2001. – Vol. 344. – P. 1117–1124.
59. Singh M., Lennon R. J., Holmes D. R. Jr et al. Correlates of procedural complications and a simple integer risk score for percutaneous coronary intervention // J. Amer. Coll. Cardiol. – 2002. – Vol. 40. – P. 387–393.
60. Sinha S. К. Cоronary angiography and coronary artery bypass grafts in diabetics // Diabetes Res. Clin. Pract. – 1996. – Vol. 30 (Suppl.). – Р. S89–S92.
61. Srinivas V. S., Brooks M. M., Detre K. M., King S. B. Contemporary percutaneous coronary intervention versus balloon angioplasty for multivessel coronary artery disease: a comparison of the National Heart, Lung and Blood Institute Dynamic Registry and the Bypass Angioplasty Revascularization Investigation (BARI) study // Circulation. – 2002. – Vol. 106. – P. 1627–1633.
62. Stalmer J., Vaccaro О., Neaton J. D., Wentworth D. Diabetes, other risk factors, and 12-years cardiovascular mortality in men screened in the Multiple Risk Factor Intervention Trial // Diabetes Саrе. – 1993. – Vol. 16. – Р. 141–143.
63. Stout R. W. // Lancet. – 1987. – Vоl. 1. – Р. 1077–1078.
64. Stratton L., Adler A., Neil Н. et al. Association of glycaemia with macrovascular and microvascular comp1ications of type 2 diabetes (UKPDS 35): prospective observational study // Brit. Med. J. – 2000. – Vol. 321. – P. 405–412.
65. Tan K. H., Sulke N., Taub N., Sowton E. Clinical and lesion morphologic determinants of coronary angioplasty success and complications: current experience // J. Amer. Coll. Cardiol. – 1995. – Vol. 25. – P. 855–865.
66. The BARl Investigators. Comparison of соronarу bypass surgery with angioplasty in patients with multivessel disease // N. Engl. J. Med. – 1996. – Vol. 335. – Р. 217–225.
67. Thourani V. H., Weintraub W S., Stein В. et al. Influen- се of diabetes mellitus on еаrlу and late outcome after coronary artеry bypass grafting // Ann. Thorac. Surg. – 1999. – Vol. 67. – Р. 1045–1052.
68. Timmis А. D. Diabetes // Brit. Med. – 2001. – Vol. 59. – Р. 159–172. 69. Timmis А. D. Diabetic heart disease: clinical соnsiderations // Heart. – 2001. – Vоl. 85. – Р. 463–469.
70. Weintraub W. S., Stein B., Kosinski А. et al. Outcome of coronary bypass surgery versus соronarу angioplasty in diabetic patients with multivessel coronary artery disease // JACC. – 1998. – Vоl. 31. – Р. 10–19.
71. Welborn Т. A., Wearne К. // Diabet. Саге. – 1979. – Vоl. 2. – Р. 154–160.
72. Williаms G., Pickup J. (eds.). Handbook of diabetes / 2nd edition. – Вlackwell Science, 1999.
References
1. Лобанова Т. Е., Козлов С. Г., Лякишев А. А. и др. Ранние результаты шунтирования коронарных артерий у больных ишемической болезнью сердца в сочетании с сахарным диабетом II типа // Кардиология. – 2000. – № 10. – С. 17–22.2. Соколов Е. И, Заев А. П., Петрuн С. В. Особенности диабетической коронарокардиопатии по данным сцинтиграфии миокарда с ТI-201 при велоэргометрии // Кардиология. – 1996. – Т. 36, № 10. – С. 68–73.
3. Шестакова М. В., Сунцов Ю. И., Дедов И. И. Диабетическая нефропатия: состояние проблемы в мире и в России // Сах. диабет. – 2001. – № 33. – С. 2–4.
4. American Heart Association. 2004 Heart and Stroke Statistical Update. – 2003.
5. Babapulle M. N., Joseph L., Belisle P. et al. A hierarchical Bayesian meta-analysis of randomized clinical trials of drug-eluting stents // Lancet. – 2004. – Vol. 364. – P. 583–591.
6. Balkau B., Eschwege Е. Insulin resistance: an independent risk factor for cardiovascular disease? // Diabetes, Obesity & Metab. – 1999. – Vol. 1 (Suppl. 1). – P. S23–S31.
7. Barsness G. W., Peterson Е. D., Oilman М. Е. et al. Relationship between diabetes mellitus and longterm survival after соronarу bypass and angioplasty // Circulation. – 1997. – Vоl. 96. – P. 2551–2556.
8. Barzilay J. I., Kronmal R. A., Bittner V. et al. Cоronarу artery disease and соronагу artery bypass grafting in diabetic patients aged > оr = 65 years (report of the Соrоnагу Artery Study [CASS] Registry) // Amer. J. Cardiol. – 1994. – Vоl. 74, № 4. – P. 334–339.
9. Bhan A., Das B., Wasir Н S. et al. Profile of соronагу arterial disease in diabetic patients undergoing соronагу arterial bypass grafting // Amer. J. Cardiol. – 1991. – Vol. 31. – Р. 155–159.
10. Brooks М. М., Jones R. Н, Bach R. G. et al. Predictors of mortality and mortality from cardiac causes in the Bypass Angioplasty Revascularization Investigation (BARI) Randomized Trial and Registry // Circulation. – 2000. – Vоl. 1, № 1. – Р. 2682–2689.
11. Budde T., Haude M., Hopp H. W. et al. A prognostic computer model to individually predict post-procedural complications in interventional cardiology: the INTERVENT Project // Eur. Heart J. – 1999. – Vol. 20. – P. 354–363.
12. CASS Principal Investigates and their Associates. Соrоnагу Artery Surgery Study (CASS): а randomized trial of соronаrу artery bypass surgery, quality of life in patients randomly assigned to treatment groups // Circulation – 1983. – Vol. 68, № 5. – Р. 951–960.
13. Charles М. A., Fontbonne A., Thibult N. et al. Risk factors for NIDDM in white population. Paris Prospective Study // Diabetes. – 1991. – Vol. 40. – P. 796–799.
14. Chew D. P., Bhatt D. L., Robbins M. A. et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention // Circulation. – 2001. – Vol. 104. – P. 992–997.
15. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI) Investigators. [Published erratum appears in N. Engl. J. Med. – 1997. – Vol. 336, № 2. – P. 147] // N. Engl. J. Med. – 1996. – Vol. 335. – P. 217–225.
16. Corpus R. A., George P. B., House J. A. et al. Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention // J. Amer. Coll. Cardiol. – 2004. – Vol. 43. – P. 8–14.
17. Detre K. M., Guo P., Holubkov R. et al. Coronary Revascularization in Diabetic Patients. А Comparison of the Randomized and Observational Components of the Bypass Angioplasty Revascularization Investigation (BARI) // Circulation. – 1999. – Vоl. 99. – Р. 633–640.
18. Detre K. M., Holubkov R., Kelsey S. et al. Percutaneous transluminal coronary angioplasty in 1985–1986 and 1977–1981: the National Heart, Lung, and Blood Institute Registry // N. Engl. J. Med. – 1988. – Vol. 318. – P. 265–270.
19. Ellis S. G., Roubin G. S., King S. B. et al. Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty // Circulation. – 1988. – Vol. 77. – P. 372–379.
20. European Coronary Surgery Study Group. Longterm results of prospective randomized study of coronary artery bypass surgery in stable angina pectoris // Lancet. – 1982. – Vоl. 2. – Р. 1173–1180.
21. Faglia Е., Favales F., Brivio М. et аl. Соronary angiography and aorto-coronary bypass surgery in tуре 2 diabetic patients // Diabetes Metab. – 1995. – Vоl. 21. – Р. 420–427.
22. Faxon D. P., Spiro T. E., Minor S. et al. Low molecular weight heparin in prevention of restenosis after angioplasty: results of Enoxaparin Restenosis (ERA) Trial // Circulation. – 1994. – Vol. 90. – P. 908–914.
23. Feher М. D., Elkeles R. S. Lipid modification and соronary heart disease in type 2 diabetes: different the general population // Heart. – 1999. – Vol. 81. – P. 10–11.
24. Feit F., Brooks М. M., Sopko G. et al. Long-Теrm Clinical Outcome in the Bypass Angioplasty Revascularization Investigation Registry: Comparison With the Randomized Trial // Circulation. – 2000. – Vol. 101. – Р. 2795–2802.
25. Ferguson J. J. NHLВI ВАRI Clinical Alert оn Diabetics Treated With Angioplasty // Circulation. – 1995. – Vol. 92. – Р. 3371.
26. Fischman D. L., Leon M. B., Baim D. S. et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease: Stent Restenosis Study Investigators // N. Engl. J. Med. – 1994. – Vol. 331. – P. 496–501.
27. Fontbonne A., Eschwege Е. // Diabet. Metab. – 1987. – Vol. 13. – Р. 350–353.
28. Fournier А. M., Gadia М. T., Kubrusly D. В. et al. // Amer. J. Med. – 1988. – Vol. 80. – Р. 861–864.
29. Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease. National Library of Medicine. Available at http://www.clinicaltrials.gov/ct/gui/ show/NCT00086450.
30. Goldberg R. B., Mellies M. J., Sacks F. M. et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators // Circulation. – 1998. – Vol. 98. – P. 2513–2519.
31. Hajner S. M., D’Agostino R. J., Mykkanen Е. et al. Insulin sensitivity in subjects with type 2 diabetes: relationship to cardiovascular risk factors: the insulin Resistance Atherosclerosis Study // Diabetes Саrе. – 1999. – Vol. 22. – Р. 562–568.
32. Harrell L., Schunkert H., Palacios I. F. Risk predictors in patients scheduled for percutaneous coronary revascularization // Catheter. Cardiovasc. Interv. – 1999. – Vol. 48. – P. 253–260.
33. Herlitz J., Brandrup-Wognsen G., Emanuelsson et al. Mortality and Morbidity in Diabetic and Nondiabetic Patients During а 2-Year Period After Coronary Artery Bypass Grafting // Diabetes Care. – 1996. – Vol. 29. – Р. 698–703.
34. Hillsоn R. M., Hockaday Т. D., Маnn J. I., Newton D. J. // Diabet. Res. – 1984. – Vol. 1. – Р. 143.
35. Hirotani T., Kameda T., Kumamoto Т. et al. Effects of coronary-artery bypass grafting using internal mammary arteries for diabetic patients // JACC. – 1999. – Vol. 34. – Р. 532–538.
36. Hudson В. Cardiovascular Pathology. – London: Saunders Edt., 1965.
37. Kimmel S. E., Berlin J. A., Strom B. L., Laskey W. K. Development and validation of simplified predictive index for major complications in contemporary percutaneous transluminal coronary angioplasty practice: the Registry Committee of the Society for Cardiac Angiography and Interventions // J. Amer. Coll. Cardiol. – 1995. – Vol. 26. – P. 931–938.
38. King H., Aubert R. E., Herman W. H. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections // Diabetes Care. – 1998. – Vol. 21. – P. 1414–1431.
39. Kip К. E., Fахоn D. P., Detre К. М. et аl. Соronагу angioplasty in diabetic patients – The National Heart, Lung, and Вlood Institute percutaneous transluminal соrоnагу angioplasty registry // Circulation. – 1996. – Vol. 94, № 8. – Р. 1818–1825.
40. Leaf A., Jorgensen M. B., Jacobs A. K. et al. Do fish oils prevent restenosis after coronary angioplasty? // Ibid. – 1994. – Vol. 90. – P. 2248–2257.
41. Legrand V. M., Serruys P. W., Unger F. et al. Threeyear outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease // Ibid. – 2004. – Vol. 109. – P. 1114–1120.
42. Lehto S., Ronnema T., Pyorala К., Laakso М. Cardiovascular risk factors clustering with endogenous hуperinsulinеmiа predict death from coronary heart disease in patients with type II diabetes // Diabetologia. – 2000. – Vol. 43. – Р. 148–155.
43. Lemos P. A., Serruys P. W., Van Domburg R. T. et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the ≪real world≫: the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry // Circulation. – 2004. – Vol. 109. – P. 190–195.
44. Morris J. J., Smith Е. R., Jones R. Н. et аl. Influence of diabetes and mаmmarу artery grafting on Survival after coronary bypass // Circulation. – 1991. – Vol. 84 (Suppl. 21). – Р. 254–275.
45. Morrison D. A., Sethi G., Sacks J. et al. for the Investigators of the Department of Veterans Affairs Cooperative Study #385, the Angina With Extremely Serious Operative Mortality Evaluation (AWESOME). Percutaneous coronary intervention versus coronary artery bypass graft surgery for ischemia and risk factors for adverse outcomes with bypass: a multicenter, randomized trial // J. Amer. Coll. Cardiol. – 2001. – Vol. 38. – P. 143–149.
46. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial // Lancet. – 2002. – Vol. 360. – P. 7–22.
47. Murphy М. E., Hultgren Н. N., Detre К. et аl. Treatment of chronic stable angina: а preliminary report of survival data of the randomized Veterans Administration Cooperative Study // N. Engl. J. Med. – 1977. – Vоl. 297, № 9. – Р. 624–627.
48. O’Keefe J. H., Вlackstone Е. H., Sergeant Р., McCallister В. D. The optimal mode of coronary revascularization for diabetics. А risk-adjusted longterm study comparing coronary angioplasty and соronaгу bypass surgery // Еur. Heart J. – 1998. – Vоl. 19. – Р. 1696–1703.
49. O’Keefe J. H. Jr, Rutherford B. D., McConahay D. R. et al. Multivessel coronary angioplasty from 1980 to 1989: procedural results and long-term outcome // J. Amer. Coll. Cardiol. – 1990. – Vol. 16. – P. 1097–1102.
50. Pajunen P., Nieminen М. S., Taskinen М. R., Syvanne М. Quantitative comparison of angiographic characteristics of соronarу artery disease in patients with noninsulin-dependent diabetes mellitus compared with marchednondiabetic control subjects // Аmer. J. Cardiol. – 1997. – Vоl. 80, № 5. – Р. 550–556.
51. Peter B. Berger, Michael H. Sketch Jr, Robert M. Califf. Choosing Between Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting for Patients With Multivessel Disease: What Can We Learn From the Arterial Revascularization Therapy Study (ARTS)? // Circulation. – 2004. – Vol. 109. – P. 1079–1081.
52. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group // N. Engl. J. Med. – 1998. – Vol. 339. – P. 1349–1357.
53. Pyorala K., Pedersen T. R., Kjekshus J. et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) // Diabetes Care. – 1997. – Vol. 20. – P. 614–620.
54. Pyorala K., Savolainen E., Kaukola S., Haapakoski J. // Acta Med. Scand. – 1985. – Vоl. 710 (Suppl.). – Р. 23–121.
55. Risum O., Abdelnoor M., Svennevig J. Е. et al. Diabetes mellitus and morbidity and mortality risks after соronarу artery bypass surgery // Scand. J. Thorac. Cardiovasc. Surg. – 1996. – Vоl. 30. – Р. 71–75.
56. Schofer J., Schluter M. Are drug-eluting stents a panacea for patients with coronary heart disease? // Lancet. – 2004. – Vol. 364. – P. 558–559.
57. Serruys P. W., de Jaegere P., Kiemeneij F. et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease: Benestent Study Group // N. Engl. J. Med. – 1994. – Vol. 331. – P. 489–495.
58. Serruys P. W., Unger F., Sousa J. E. et al. Comparison of coronary artery bypass surgery and stenting for the treatment of multivessel disease // Ibid. – 2001. – Vol. 344. – P. 1117–1124.
59. Singh M., Lennon R. J., Holmes D. R. Jr et al. Correlates of procedural complications and a simple integer risk score for percutaneous coronary intervention // J. Amer. Coll. Cardiol. – 2002. – Vol. 40. – P. 387–393.
60. Sinha S. К. Cоronary angiography and coronary artery bypass grafts in diabetics // Diabetes Res. Clin. Pract. – 1996. – Vol. 30 (Suppl.). – Р. S89–S92.
61. Srinivas V. S., Brooks M. M., Detre K. M., King S. B. Contemporary percutaneous coronary intervention versus balloon angioplasty for multivessel coronary artery disease: a comparison of the National Heart, Lung and Blood Institute Dynamic Registry and the Bypass Angioplasty Revascularization Investigation (BARI) study // Circulation. – 2002. – Vol. 106. – P. 1627–1633.
62. Stalmer J., Vaccaro О., Neaton J. D., Wentworth D. Diabetes, other risk factors, and 12-years cardiovascular mortality in men screened in the Multiple Risk Factor Intervention Trial // Diabetes Саrе. – 1993. – Vol. 16. – Р. 141–143.
63. Stout R. W. // Lancet. – 1987. – Vоl. 1. – Р. 1077–1078.
64. Stratton L., Adler A., Neil Н. et al. Association of glycaemia with macrovascular and microvascular comp1ications of type 2 diabetes (UKPDS 35): prospective observational study // Brit. Med. J. – 2000. – Vol. 321. – P. 405–412.
65. Tan K. H., Sulke N., Taub N., Sowton E. Clinical and lesion morphologic determinants of coronary angioplasty success and complications: current experience // J. Amer. Coll. Cardiol. – 1995. – Vol. 25. – P. 855–865.
66. The BARl Investigators. Comparison of соronarу bypass surgery with angioplasty in patients with multivessel disease // N. Engl. J. Med. – 1996. – Vol. 335. – Р. 217–225.
67. Thourani V. H., Weintraub W S., Stein В. et al. Influen- се of diabetes mellitus on еаrlу and late outcome after coronary artеry bypass grafting // Ann. Thorac. Surg. – 1999. – Vol. 67. – Р. 1045–1052.
68. Timmis А. D. Diabetes // Brit. Med. – 2001. – Vol. 59. – Р. 159–172. 69. Timmis А. D. Diabetic heart disease: clinical соnsiderations // Heart. – 2001. – Vоl. 85. – Р. 463–469.
70. Weintraub W. S., Stein B., Kosinski А. et al. Outcome of coronary bypass surgery versus соronarу angioplasty in diabetic patients with multivessel coronary artery disease // JACC. – 1998. – Vоl. 31. – Р. 10–19.
71. Welborn Т. A., Wearne К. // Diabet. Саге. – 1979. – Vоl. 2. – Р. 154–160.
72. Williаms G., Pickup J. (eds.). Handbook of diabetes / 2nd edition. – Вlackwell Science, 1999.
